143 related articles for article (PubMed ID: 2879057)
1. Pharmacological studies of 2-(3-(3-(1-piperidinylmethyl)-phenoxy)propylamino)-4 (3H)-quinazolinone (NO-794), a new histamine H2-receptor antagonist.
Oshita M; Morikawa K; Aratani T; Kato H; Ito Y
Jpn J Pharmacol; 1986 Oct; 42(2):229-35. PubMed ID: 2879057
[TBL] [Abstract][Full Text] [Related]
2. Syntheses and gastric acid antisecretory properties of the H2-receptor antagonist. N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]thieno[3,4-d]isot hiazol-3-amine 1,1-dioxide and related derivatives.
Santilli AA; Scotese AC; Morris RL; Schiehser GA; Teller DM; Nielsen ST; Strike DP
J Med Chem; 1988 Jul; 31(7):1480-6. PubMed ID: 2898534
[TBL] [Abstract][Full Text] [Related]
3. JB-9322, a new selective histamine H2-receptor antagonist with potent gastric mucosal protective properties.
Palacios B; Montero MJ; Sevilla MA; Román LS
Br J Pharmacol; 1995 May; 115(1):57-66. PubMed ID: 7647984
[TBL] [Abstract][Full Text] [Related]
4. H2-receptor antagonist and gastric acid antisecretory properties of Wy-45,662.
Nielsen ST
Agents Actions; 1986 Nov; 19(3-4):158-63. PubMed ID: 2881454
[TBL] [Abstract][Full Text] [Related]
5. Activity of the new histamine H2-receptor antagonist zolantidine at cardiac and gastric H2-receptors.
Coruzzi G; Adami M; Pozzoli C; Poli E; Bertaccini G
Pharmacology; 1994 Feb; 48(2):69-76. PubMed ID: 7907797
[TBL] [Abstract][Full Text] [Related]
6. FR145715, a novel histamine H2 receptor antagonist, with specific anti-Helicobacter pylori activities.
Ishikawa H; Ito H; Higaki M; Higaki M; Matsumoto Y; Kamimura T; Katsura Y; Tomishi T; Inoue Y; Takasugi H; Tomoi M; Krakowka S; Yoshida K
Eur J Pharmacol; 1999 Aug; 378(3):299-310. PubMed ID: 10493106
[TBL] [Abstract][Full Text] [Related]
7. CP-66,948: an antisecretory histamine H2-receptor antagonist with mucosal protective properties.
Hakkinen JP; Holt WF; Goddard CJ; Oates PJ; Murphy WR; Maciejko JJ; Reiter LA
Dig Dis Sci; 1991 Dec; 36(12):1721-8. PubMed ID: 1748041
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of JB-9315, a new selective histamine H2-receptor antagonist.
Palacios B; Montero MJ; Sevilla MA; San Román L
Gen Pharmacol; 1998 Feb; 30(2):181-9. PubMed ID: 9502172
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the H2 receptor antagonist and gastric acid antisecretory properties of Wy-45,727.
Nielsen ST
J Pharmacol Exp Ther; 1987 Aug; 242(2):607-13. PubMed ID: 2886646
[TBL] [Abstract][Full Text] [Related]
10. Structural requirements for roxatidine in the stimulant effect of rat gastric mucin synthesis and the participation of nitric oxide in this mechanism.
Ichikawa T; Ishihara K; Saigenji K; Hotta K
Br J Pharmacol; 1997 Nov; 122(6):1230-6. PubMed ID: 9401791
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cimetidine with new H2-antagonists in rabbit and guinea pig gastric cells.
Batzri S; Harmon JW; Toles R
Eur J Pharmacol; 1983 Oct; 94(1-2):1-8. PubMed ID: 6140169
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of ORF 17578, a new histamine H2-receptor antagonist: comparison with cimetidine and ranitidine.
Katz LB; Scott CK; Shriver DA
J Pharmacol Exp Ther; 1986 May; 237(2):404-10. PubMed ID: 2871172
[TBL] [Abstract][Full Text] [Related]
13. Effects of H2-receptor antagonists on 3H-cimetidine binding and histamine-stimulation of cellular cAMP in isolated guinea pig gastric glands.
Tanaka A; Nishihara S; Misawa T; Ibayashi H
Jpn J Pharmacol; 1987 Sep; 45(1):97-105. PubMed ID: 2890783
[TBL] [Abstract][Full Text] [Related]
14. Effects of FRG-8701 on gastric acid secretion, gastric mucosal lesions by necrotizing agents and experimental gastric or duodenal ulcer in rats.
Shibata M; Yamaura T; Sekine A; Nishikawa M; Chida Y; Ohnishi H
Jpn J Pharmacol; 1990 Nov; 54(3):277-85. PubMed ID: 1982548
[TBL] [Abstract][Full Text] [Related]
15. Antisecretory effects of two new histamine H2-receptor antagonists.
Bickel M; Herling AW; Rising TJ; Wirth K
Arzneimittelforschung; 1986 Sep; 36(9):1358-63. PubMed ID: 2878669
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea.
Sekiguchi H; Hamada K; Kobayashi F; Taga F; Uchida H
Arzneimittelforschung; 1993 Feb; 43(2):129-33. PubMed ID: 8096132
[TBL] [Abstract][Full Text] [Related]
17. A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.
Cavanagh RL; Usakewicz JJ; Buyniski JP
J Pharmacol Exp Ther; 1983 Jan; 224(1):171-9. PubMed ID: 6129316
[TBL] [Abstract][Full Text] [Related]
18. Apparent irreversible H2-receptor blocking and prolonged gastric antisecretory activities of 3-N-(3-[3-(1-piperidinomethyl)phenoxy]propyl) amino-4-amino-1,2,5-thiadiazole-1-oxide (L-643, 441).
Torchiana ML; Pendleton RG; Cook PG; Hanson CA; Clineschmidt BV
J Pharmacol Exp Ther; 1983 Mar; 224(3):514-9. PubMed ID: 6131118
[TBL] [Abstract][Full Text] [Related]
19. Histamine H2-receptor antagonism of T-593: studies on positive chronotropic responses in guinea pig atria.
Arai H; Nakagawa M; Tanada K; Yamaguchi H; Hirai S
Jpn J Pharmacol; 1994 Apr; 64(4):251-6. PubMed ID: 7914553
[TBL] [Abstract][Full Text] [Related]
20. Structural modification of H2-receptor antagonists provide post-H2-receptor gastric antisecretory activity.
Nielsen ST; Dove PA; Strike DP; Schiehser GA
Drugs Exp Clin Res; 1987; 13(5):297-304. PubMed ID: 2890506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
